BioLineRx Ltd
NASDAQ: BLRX · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
BioLineRx Ltd (BLRX) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2008 | — | $-32.06M | — | — | — |
| 2009 | $16.27M | $-15.66M | 61.86% | -99.02% | -96.26% |
| 2010 | $31.89M | $2.10M | 77.40% | 11.61% | 6.57% |
| 2011 | $63.91M | $-13.19M | -0.68% | -25.61% | -20.63% |
| 2012 | $113.16M | $-20.42M | -0.35% | -18.69% | -18.04% |
| 2013 | $113.16M | $-17.64M | -0.28% | -15.03% | -15.59% |
| 2014 | $0.00 | $-10.17M | — | — | — |
| 2015 | $0.00 | $-14.40M | — | — | — |
| 2016 | $0.00 | $-15.84M | — | — | — |
| 2017 | $0.00 | $-24.35M | — | — | — |
| 2018 | $0.00 | $-22.96M | — | — | — |
| 2019 | $0.00 | $-25.45M | — | — | — |
| 2020 | $0.00 | $-30.02M | — | — | — |
| 2021 | $0.00 | $-27.05M | — | — | — |
| 2022 | $0.00 | $-24.95M | — | — | — |
| 2023 | $4.80M | $-60.61M | 23.08% | -1,035.29% | -1,262.79% |
| 2024 | $28.94M | $-9.22M | 67.99% | -70.52% | -31.86% |
| 2025 | $1.19M | $-1.18M | 36.19% | -871.78% | -99.58% |
Frequently asked questions
What is BioLineRx Ltd's revenue?
BioLineRx Ltd's trailing twelve-month revenue is $1.40M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is BLRX?
In its most recent fiscal year, BLRX ran a gross margin of 36.19%, an operating margin of -871.78%, and a net margin of -99.58%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does BLRX generate?
BLRX produced $-8.16M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is BLRX's balance sheet healthy?
BLRX holds $3.25M in cash and equivalents against $4.46M in long-term debt, on $18.20M of shareholder equity. That debt is best read against the cash flow the business throws off each year.